PCV chemotherapy for recurrent glioblastoma mutiforme

A. C. Kappelle; T. J. Postma; M. J.B. Taphoorn; G. J. Groeneveld; M. J. Van den Bent; C. J. Van Groeningen; B. A. Zonnenberg; K. C.A. Sneeuw; J. J. Heimans

doi:10.1212/WNL.56.1.118

PCV chemotherapy for recurrent glioblastoma mutiforme

A. C. Kappelle
, T. J. Postma^*
, M. J.B. Taphoorn
, G. J. Groeneveld
, M. J. Van den Bent
, C. J. Van Groeningen
, B. A. Zonnenberg
, K. C.A. Sneeuw
, J. J. Heimans

^*Corresponding author for this work

Neurology

VU University Medical Center
Vrije Universiteit Amsterdam
Utrecht University

Research output: Contribution to journal › Article › Academic › peer-review

93 Citations (Scopus)

Abstract

The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%). In 16 patients (25%), stable disease was observed. Median TTP and survival were 13 and 33 weeks. Age < 40 years and Karnofsky Performance Status ≥ 90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.

Original language	English
Pages (from-to)	118-120
Number of pages	3
Journal	Neurology
Volume	56
Issue number	1
DOIs	https://doi.org/10.1212/WNL.56.1.118
Publication status	Published - 9 Jan 2001

Access to Document

10.1212/WNL.56.1.118

Cite this

@article{50f514235fa1448da2e7cd31ed4fff83,

title = "PCV chemotherapy for recurrent glioblastoma mutiforme",

abstract = "The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3\%) and five patients (8\%). In 16 patients (25\%), stable disease was observed. Median TTP and survival were 13 and 33 weeks. Age < 40 years and Karnofsky Performance Status ≥ 90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.",

author = "Kappelle, \{A. C.\} and Postma, \{T. J.\} and Taphoorn, \{M. J.B.\} and Groeneveld, \{G. J.\} and \{Van den Bent\}, \{M. J.\} and \{Van Groeningen\}, \{C. J.\} and Zonnenberg, \{B. A.\} and Sneeuw, \{K. C.A.\} and Heimans, \{J. J.\}",

year = "2001",

month = jan,

day = "9",

doi = "10.1212/WNL.56.1.118",

language = "English",

volume = "56",

pages = "118--120",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams \& Wilkins",

number = "1",

}

TY - JOUR

T1 - PCV chemotherapy for recurrent glioblastoma mutiforme

AU - Kappelle, A. C.

AU - Postma, T. J.

AU - Taphoorn, M. J.B.

AU - Groeneveld, G. J.

AU - Van den Bent, M. J.

AU - Van Groeningen, C. J.

AU - Zonnenberg, B. A.

AU - Sneeuw, K. C.A.

AU - Heimans, J. J.

PY - 2001/1/9

Y1 - 2001/1/9

N2 - The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%). In 16 patients (25%), stable disease was observed. Median TTP and survival were 13 and 33 weeks. Age < 40 years and Karnofsky Performance Status ≥ 90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.

AB - The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%). In 16 patients (25%), stable disease was observed. Median TTP and survival were 13 and 33 weeks. Age < 40 years and Karnofsky Performance Status ≥ 90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.

UR - https://www.scopus.com/pages/publications/0035830431

U2 - 10.1212/WNL.56.1.118

DO - 10.1212/WNL.56.1.118

M3 - Article

AN - SCOPUS:0035830431

SN - 0028-3878

VL - 56

SP - 118

EP - 120

JO - Neurology

JF - Neurology

IS - 1

ER -

PCV chemotherapy for recurrent glioblastoma mutiforme

Abstract

Access to Document

Other files and links

Fingerprint

Cite this